Veriheal

MARCH 18, 2021

It is quite common for cannabis researchers to make use of vertebrates since animals with spines have an endocannabinoid system (ECS), such as mice and rats. Cats do have an ECS, but why use them for research*? As the team stated, aging cats develop cognitive dysfunction as they become older, much like humans.

CBD 95

CBD Research and Development Pets Treatment 95

Cannabis Law Report

MARCH 24, 2022

Rather, it’s a modest bipartisan piece of legislation that’s simply meant to promote research into marijuana. JUST IN: The Senate passed my bill with Senators Grassley and Schatz to cut red tape around the research process of marijuana and marijuana-derived medications. — Senator Dianne Feinstein (@SenFeinstein) March 24, 2022.

Research and Development 52

Research and Development Legislation Patients Safety 52

Cannabis Law Report

MAY 18, 2022

Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. Validcare contracted with 17 CBD companies and acted as the Contract Research Organization, which included gaining feedback from FDA on the protocol, conducting the study and publishing its results.

Safety 52

Safety Hemp Research and Development Data 52

Cannabis Law Report

MAY 18, 2022

NEW STUDY DEMONSTRATES CBD’S STRONG SAFETY PROFILE , AMPLIFIES CALLS FOR FDA REGULATION. Observational Data Collected On Long-term Consumption of Oral C BD Shows No Correlation To Safety Issues Raised by FDA. The study abstract is available here. The methods for both phases were the same.

Safety 52

Safety Hemp Research and Development Data 52

Cannabis Law Report

JULY 8, 2021

A Swinburne study into the effects on medical cannabis on driving ability has received $358,980 in funding from the federal government’s Road Safety Innovation Fund. The study is the first of its kind and will be conducted within Swinburne’s Drugs and Driving Research unit, which is led by Professor Downey. ‘We Source: [link].

Medicine 98

Medicine Research and Development Safety THC 98

The Cannigma

FEBRUARY 2, 2021

In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. However, the survey also revealed that, among the Parkinson’s disease patients , there was a noticeable knowledge gap concerning the different methods of consumption available and the individual effects of THC and CBD.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

United Patients Group

SEPTEMBER 7, 2023

As the perception of medical marijuana evolves and an increasing number of individuals explore its therapeutic potential, it’s crucial to develop a comprehensive understanding of cannabis’ impact on bodily systems. One area of interest and ongoing research is the relationship between cannabis and the immune system.

Research and Development 111

Research and Development Conditions Cannabinoids Patients 111

MMJ Recs

JANUARY 2, 2024

As scientific research delves deeper into medical cannabis for cancer patients, MMJ’s potential has come to the forefront, offering new hope for individuals grappling with the complexities of cancer. However, further research is essential to understand its mechanisms and establish optimal therapeutic doses.

Treatment 98

Treatment Therapy Research and Development Patients 98

MMJ Recs

APRIL 25, 2024

However, the production of medical cannabis involves a meticulous process to ensure quality, potency, and safety for patients. Utilizing nutrient-rich soil or hydroponic systems aids in supplying essential nutrients to the plants, fostering healthy development.

Marijuana 52

Marijuana Cultivation Safety Trichome 52

Cannabis Law Report

JANUARY 31, 2022

TSX-V:NUMI, OTC:LKYSF) said that its research facility– Numinus Bioscience– has been included on Health Canada’s list of federally licensed psilocybin producers. This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. Numinus Wellness Inc.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

JUNE 19, 2022

Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. This latest partnership further strengthens Beckley Psytech’s digital strategy to develop personalised, end-to-end treatment programmes for patients in areas of significant unmet medical need.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Cannabis Law Report

MAY 29, 2022

Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

WeedAdvisor

JULY 4, 2019

Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety. A Vicious Circle. .

DEA 111

DEA Research and Development Clinical Trials Cannabis 111

MMJ Recs

MARCH 16, 2024

Economic Growth and Job Creation of the medical marijuana industry The medical cannabis sector serves as a catalyst for economic expansion and workforce development in regions where it’s legalized. Moreover, ensuring product quality and safety throughout the supply chain is paramount to maintain patient trust and regulatory compliance.

Supply Chain 105

Supply Chain Research and Development Marijuana Seed-To-Sale 105

Cannabis Law Report

DECEMBER 26, 2021

“With the filing of our provisional patent application, Entheon is building an IP foundation to better facilitate safe and precise use of psychedelics to deliver improved patient outcomes.” . – December 16, 2021) – Entheon Biomedical Corp. ” In Vivo Toxicity Assays Completed. About Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

APRIL 13, 2022

Delic Labs’ latest exemptions enable the Company to develop innovative analytical methods for psychedelic research. Last year, the lab also applied for a Dealer’s License with the intent of commercializing psilocybin research and associated intellectual property (IP) for medical and research purposes.

Research and Development 52

Research and Development Treatment Extraction Medicine 52

MMJ Recs

NOVEMBER 20, 2023

These two cannabinoids represent just a fraction of the compounds within the cannabis plant, and ongoing research continues to uncover the potential of other lesser-known cannabinoids. These compounds may help reduce symptoms and improve the quality of life for patients.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Cannabis Law Report

JULY 28, 2021

InnarisBio), to develop a novel sol-gel intranasal drug delivery technology to improve treatments for mental health disorders. InnarisBio will collaborate with UniQuest, UQ’s Dr Parekh and his research team to formulate and develop bespoke sol-gel formulations for several psychedelic and non-psychedelic compounds nominated by InnarisBio.

Research and Development 98

Research and Development Programs Treatment Media 98

Cannabis Law Report

JULY 19, 2021

We don’t want to see research fall to the wayside as it has for cannabis, both in Canada and globally. We are in a mental health crisis and its critical to ensure that we conduct clinical trials to demonstrate safety, and efficacy up to and including phase 3 large scale clinical trials.

Clinical Trials 98

Clinical Trials Research and Development Hybrid Medicine 98

Cannabis Law Report

OCTOBER 6, 2021

The lab currently holds a 56 Research Exemption for chemistry analytics on psilocybin mushrooms. Additionally, the lab has applied for a Dealer’s License and intends to eventually commercialize its psilocybin research and associated intellectual property (IP) for medical and research purposes.

Research and Development 52

Research and Development Extraction Treatment Safety 52

Veriheal

JANUARY 18, 2024

In a revolutionary development that reflects the ever-changing healthcare arena, cannabis nursing has earned official recognition as a specialized field in nursing. Patient education is their primary focus, as they provide knowledgeable guidance on the therapeutic benefits and potential risks of cannabis.

Education 113

Education Therapy Patients Research and Development 113

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD.

DEA 66

DEA Clinical Trials THC Research and Development 66

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? and ‘The Perioperative Considerations for the Patient Utilizing Cannabinoid-based Medicines and Products.’ million medical marijuana patients nationwide. So, why did this educational gap develop? Unfortunately, this did not occur.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

JUNE 5, 2019

The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Today (30 May) at 09.30 Formula 1 THC is higher than CBD.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

MMJ Recs

MARCH 14, 2024

Qualifying Conditions for Medical Marijuana in West Virginia West Virginia’s medical marijuana program encompasses an extensive list of qualifying conditions, providing access to patients with various chronic or debilitating diseases.

Dispensary 52

Dispensary Programs Legalization Marijuana 52

MMJ Recs

NOVEMBER 17, 2023

This article explores the profound impact of MMJ on Maryland communities, shedding light on the medical marijuana benefits experienced by patients and the positive effects it has had on the state’s communities. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

SEPTEMBER 23, 2021

BIMA was an Open-label safety, tolerability and proof-of-concept study to investigate the role of MDMA-Assisted Psychotherapy in treating patients with alcohol use disorder (AUD). Awakn will now be able to accelerate its clinical research into a phase IIb randomized controlled trial (RCT) in the U.K.

Research and Development 52

Research and Development Therapy Treatment Data 52

Cannabis Law Report

DECEMBER 5, 2021

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Adverse mental events were reported as well, however, more research should be performed to assess well this outcome.

Safety 52

Safety Cannabinoids Events Data 52

MMJ Recs

APRIL 30, 2024

From the moment a cannabis seed is planted to the point it reaches the hands of a patient, a complex and highly regulated process unfolds. These regulations aim to maintain quality control, prevent diversion to the illicit market, and ensure patient safety.

Cultivation 52

Cultivation Supply Chain Extraction Marijuana 52

Cannabis Law Report

FEBRUARY 28, 2022

In the past two decades, pioneering research has rekindled interest in the therapeutic use of psychedelic substances such as psilocybin, ibogaine, and dimethyltryptamine (DMT). Indigenous communities have used them for centuries, and researchers studied them in the 1950s and ‘60s. Glenn Cohen & Mason Marks. 20 February 2022.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

DECEMBER 3, 2021

We look forward to sharing clinical trial data supporting the potential of ganaxolone to treat a range of seizure disorders as well as research data highlighting the impact that seizures can have on developmental progressions and quality of life in children with CDD.”. Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

AUGUST 22, 2021

Biotech startup to bring safety and efficacy to the emerging psychedelic industry, brings on University of Michigan Researcher as Chief Science Officer. Nearly all forms of research being done on psychedelics are via the digestive tract, which slows uptake, requires higher dosage, and may lead to harmful side effects in the body.

Pharmaceutical 98

Pharmaceutical Medicine Research and Development Therapy 98

Cannabis Law Report

JUNE 17, 2021

goodblend™ Texas , a retail brand of Parallel , one of the nation’s largest privately-held multi-state cannabis operators, today announced the launch of the first cannabinol (CBN) products for patients registered in the Texas Compassionate Use Program. goodblend™ Texas, a retail brand of Parallel.

Patients 97

Patients Programs Sleep Retail 97

FloridaMarijuana.net

JULY 8, 2018

The National Academies of Sciences reports that PTSD is a stressor-related disorder which develops as a result of a patient’s exposure to a traumatic event. The psychological symptoms that develop because of the trauma affect mood, cognition, memories (both suppression and the inability to form new memories) and physical health.

Strains 190

Strains Indica Hybrid Research and Development 190

Canna Law Blog

SEPTEMBER 12, 2022

The regulations take the form of a decree issued by President Laurentino Cortizo Cohen, which “regulates the use and access to the product and its derivatives, for therapeutic, medical, veterinary, scientific and research purposes throughout the country.” The decree also establishes a patient registry.

Research and Development 91

Research and Development Safety Medicine Agriculture 91